Occupational Activity
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
Glucagon-Like Peptide 1, Industry, Market, Effectiveness, Oral cavity, production, injectables, Orals, orforglipron, Manufacture, GLP-1s
23andMe files for bankruptcy as CEO Anne Wojcicki steps down to become bidder
Bankruptcy, CEO, Anne, Customer
A closer look at pharmas top patent losses in 2025
Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023
Drugmakers renew concerns over UK’s attractiveness for investment
Investments, UK, UK ‘s, concerns, Industry, attractiveness
Trump Administration Considers Cuts to CDC’s HIV Prevention Program, Raising Concerns
HIV prevention, CDC funding cuts, Trump administration, public health, HIV/AIDS advocacy
Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment
Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile
Lonza’s Vision for the Future: A Fireside Chat with New CEO Wolfgang Wienand
Lonza, Wolfgang Wienand, CDMO, Pharmaceutical manufacturing, Biologics, Cell and gene therapy, Small molecules, Leadership transition, Industry outlook
Future-proofing gene therapy assays: Validation strategies for long-term success
Long-term, Validation, Biological Assay, Develop
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash
J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms
Carvykti, Johnson and Johnson, Investments, J&J, Facility (object), Multiple Myeloma, production, competition